SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that optical genome mapping (OGM) was included for the first time in Thompson and Thompson Genetics and Genomics in Medicine, 9th edition, a textbook regularly used for medical students, genetic counseling students, students in laboratory medicine, and more advanced trainees pursuing American Board of Medical Genetics and Genomics (ABMGG) residency and laboratory fellowships in clinical biochemical genetics, laboratory genetics and genomics, and clinical molecular genetics. The publication, which was last updated in 2015, includes information on new discoveries in the fields of genetics and genomics, the latest technologies in genome analysis, and new diagnoses these methods can enable.
The book’s authors describe OGM as a powerful tool for genome analysis, due to its ability to detect and validate structural variants (SVs) that sequencing techniques may miss. They also note that, when compared to long-read sequencing (LRS), OGM can be less expensive and can resolve complex SVs with greater precision, showing its potential as a tool in clinical research investigations.
“We are thrilled to see OGM included in the newest edition of Thompson and Thompson Genetics and Genomics in Medicine, which is the primary training manual for trainees and fellows seeking ABMGG certifications in clinical biochemical genetics, laboratory genetics and genomics, and clinical molecular genetics. The book plays an important role in directing the genomics community toward emerging techniques, and in comparing different methods of genome analysis,” commented Alka Chaubey, PhD, FACMG, chief medical officer of Bionano.
“Inclusion in this book is a significant milestone for OGM and for people in the various fields of genome analysis who are looking for ways to move the community forward. We were pleased to see the authors note OGM’s ability to detect clinically relevant SVs that other methods, including LRS, miss, while citing OGM’s potential lower cost and greater accuracy, particularly as the SVs detected by OGM in research may ultimately lead to improved diagnosis and detection of genetic disorders,” added Erik Holmlin, PhD, president and chief executive officer of Bionano.
The publication can be found here.
About Bionano
Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. The Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. The Company additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis technology. For more information, visit www.bionano.com, www.bionanolaboratories.com or www.purigenbio.com.
Unless specifically noted otherwise, Bionano’s OGM products are for research use only and not for use in diagnostic procedures.
Forward-Looking Statements of Bionano
This press release contains forward-looking statements contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “can,” “may,” “potential” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances and the negatives thereof) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the potential of OGM to reveal SVs that sequencing techniques may miss; the potential of OGM to resolve complex SVs with greater precision and less expensively when compared to LRS; the potential of OGM as a tool in clinical research investigations; and other statements that are not historical facts.
Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of geopolitical and macroeconomic developments, such as recent and future bank failures, the ongoing Ukraine-Russia conflict, related sanctions, the Israel-Hamas war, and any global pandemics, on our business and the global economy; challenges inherent in developing, manufacturing and commercializing products; our ability to further deploy new products and applications and expand the markets for our technology platforms; failure of our OGM solutions to be adopted as a tool in clinical research investigations; the failure of OGM to detect SVs that sequencing technologies miss; the failure of OGM to detect SVs more precisely or less expensively when compared to LRS; ; future publications that contradict or do not support the statements in the newest edition of Thompson and Thompson Genetics and Genomics in Medicine; our expectations and beliefs regarding future growth of the business and the markets in which we operate; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts and our ability to continue as a “going concern”; and including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2022 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We are under no duty to update any of these forward-looking statements after the date they are made to conform these statements to actual results or revised expectations, except as required by law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date the statements are made. Moreover, except as required by law, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements contained in this press release.
CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionano.com
Investor Relations:
David Holmes
Gilmartin Group
+1 (858) 888-7625
IR@bionano.com
